title: Macrophage-mediated renal injury is dependent on signaling via the JNK pathway.
abstract: Macrophage accumulation is a prominent feature in most forms of human glomerulonephritis and correlates with renal dysfunction. Macrophages can directly mediate acute renal injury in animal models, but the mechanisms of macrophage activation required for mediating renal injury are unknown. This study examined whether activation of the Jun amino terminal kinase (JNK) signaling pathway is necessary for macrophage-mediated renal injury. An adoptive transfer model was used in which rats were immunized with sheep IgG (day -5), made leukopenic by administration of cyclophosphamide (CyPh) (day -2), and then injected with sheep anti-glomerular basement membrane (GBM) serum (day 0). Animals were then given an intravenous injection of bone marrow-derived macrophages (BMM) (day 1) and killed 24 h later (day 2). The induction of proteinuria and glomerular cell proliferation (PCNA+ cells) in CyPh-treated anti-GBM disease was dependent on transfer of BMM. Exposure of BMM to the specific JNK inhibitor, SP600125, for 3 h before adoptive transfer had no effect on glomerular accumulation of BMM in CyPh-treated anti-GBM disease. However, SP600125 treatment of BMM caused a 75% reduction in proteinuria and a 70% reduction in glomerular cell proliferation (P < 0.01 versus vehicle or untreated BMM). In conclusion, this study has defined a critical role for the JNK signaling pathway in macrophage-mediated renal injury.
authors.affiliation: Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.
authors.forename: Yohei
authors.initials: Y
authors.lastname: Ikezumi
authors.forename: Lyn
authors.initials: L
authors.lastname: Hurst
authors.forename: Robert C
authors.initials: RC
authors.lastname: Atkins
authors.forename: David J
authors.initials: DJ
authors.lastname: Nikolic-Paterson
mesh_terms: D000818:Animals; D000873:Anthracenes / Q000494:pharmacology; D000906:Antibodies / Q000737:chemistry; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D001323:Autoantibodies; D015153:Blotting, Western; D001854:Bone Marrow Cells / Q000166:cytology; D003520:Cyclophosphamide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005434:Flow Cytometry; D007074:Immunoglobulin G / Q000737:chemistry; D007150:Immunohistochemistry; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism*; D007668:Kidney / Q000293:injuries* / Q000378:metabolism; D007970:Leukopenia / Q000139:chemically induced; D048670:MAP Kinase Kinase 4; D008264:Macrophages / Q000166:cytology / Q000378:metabolism*; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism; D051381:Rats; D012756:Sheep; D015398:Signal Transduction; D013997:Time Factors
chemical_list: D000873:Anthracenes; D000906:Antibodies; D018906:Antineoplastic Agents, Alkylating; D001323:Autoantibodies; D004791:Enzyme Inhibitors; D007074:Immunoglobulin G; C051951:antiglomerular basement membrane antibody; C432165:pyrazolanthrone; D009569:Nitric Oxide; D003520:Cyclophosphamide; D048031:JNK Mitogen-Activated Protein Kinases; D048670:MAP Kinase Kinase 4; D020929:Mitogen-Activated Protein Kinase Kinases